Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.

Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.

Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.

Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.

The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.

Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.

مُعامل القيمة السوقية إلى الأرباح لـ Cynata Therapeutics هو ؜-٤٫٢٤.

مُعامِل القيمة إلى المبيعات Cynata Therapeutics هو ٩٨٫٩١.

نقاط جودة AlleAktien لـ Cynata Therapeutics هي 5/10.

Cynata Therapeutics الإيرادات هي ٤١٧٬٧١٠٫٠٠ AUD.

صافي الربح Cynata Therapeutics هو ؜-٩٫٧٤ مليون. AUD.

Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.

يوزع Cynata Therapeutics أرباحًا قدرها 0 AUD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Cynata Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـCynata Therapeutics هو AU000000CYP7.

رمز WKN لـ Cynata Therapeutics هو A1W8VE.

الرمز المُختصر لـ Cynata Therapeutics هو CYP.AX.

خلال آخر 12 شهراً، دفعت Cynata Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Cynata Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 AUD.

نسبة توزيعات الأرباح الحالية لـ Cynata Therapeutics هي .

Cynata Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Cynata Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 AUD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Cynata Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 AUD من Cynata Therapeutics المُعلن عنها في ١‏/١١‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١‏/١١‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١١‏/٢٠٢٤.

في العام 2023، وزعت Cynata Therapeutics 0 AUD كأرباح أسهم.

يتم توزيع أرباح Cynata Therapeutics بالعملة AUD.